Saxenda in South Asian Patients: Documented Efficacy Gaps and Pharmacogenomic Considerations

Why South Asian Patients Require Separate Efficacy Analysis

South Asian populations carry a distinct cardiometabolic risk profile that changes how obesity drugs should be evaluated. The WHO Expert Consultation published in 2004 recommended lowering the obesity BMI cutoff to 27.5 kg/m² for Asian populations, reflecting the observation that metabolic complications develop at body weights considered "normal" by Western standards [1]. Type 2 diabetes prevalence among South Asians living in the UK is roughly four times that of white Europeans at equivalent BMI levels [2].

The BMI Paradox in South Asian Metabolic Disease

This disparity is not simply a matter of lifestyle. South Asians accumulate visceral adipose tissue disproportionately, and their pancreatic beta-cell reserve tends to be lower at baseline. A 2019 analysis in The Lancet Diabetes & Endocrinology found that South Asians develop insulin resistance at a mean BMI of 23.9, compared to 29.1 in white Europeans [3]. That gap of roughly 5 BMI points means a South Asian patient with a BMI of 26 may already have the metabolic burden that a European-descent patient would not experience until BMI 31 or higher.

Earlier Disease Onset and Treatment Timing

The ICMR-INDIAB study, the largest epidemiological diabetes survey in India (N=124,024), documented a type 2 diabetes prevalence of 7.3% nationally, with rates exceeding 10% in urban areas [4]. Onset occurs a full decade earlier on average. This compressed timeline raises a pointed clinical question: if we are treating metabolic disease earlier, are we evaluating anti-obesity medications early enough and in the right populations?

What the SCALE Trials Showed, and What They Missed

The SCALE Obesity and Prediabetes trial (N=3,731) remains the largest randomized controlled trial of liraglutide 3 mg for weight management. Participants receiving liraglutide lost a mean of 8.0% of total body weight at 56 weeks, compared to 2.6% with placebo [5]. The results led to FDA approval of Saxenda in December 2014.

Limited Ethnic Stratification

The trial enrolled participants across 27 countries, but the published efficacy data were not stratified by South Asian ethnicity in the primary analysis. The majority of participants were white (approximately 85%). Asian participants as a broad category represented a small subset, and the subgroup was not powered to detect clinically meaningful differences in weight-loss response [5].

This is a recurring problem. A 2021 systematic review in Obesity Reviews examined 48 major anti-obesity medication trials and found that only 12% reported outcomes stratified by Asian ethnicity, and none separated South Asian from East Asian cohorts [6]. The distinction matters because South Asian and East Asian populations differ in body composition, fat distribution, and metabolic phenotype.

SCALE Maintenance and Diabetes Subtrials

The SCALE Maintenance trial (N=422) and the SCALE Diabetes trial (N=846) similarly lacked ethnicity-specific subgroup analyses for South Asian patients [7][8]. In the diabetes subtrial, liraglutide 3 mg produced a mean weight loss of 6.0% versus 2.0% with placebo at 56 weeks, with an HbA1c reduction of 1.3 percentage points. Whether South Asian participants, who tend to have lower BMI at diabetes diagnosis, experienced equivalent or lesser weight reduction remains unknown from these data.

Pharmacogenomic Factors That May Influence Liraglutide Response

Liraglutide binds the GLP-1 receptor encoded by the GLP1R gene on chromosome 6p21.2. Several single-nucleotide polymorphisms in GLP1R have been associated with variable drug response. The variant rs6923761 (Gly168Ser) has been linked to reduced GLP-1 receptor signaling efficiency in multiple pharmacogenomic studies [9].

GLP1R Variants and Allele Frequency Differences

According to PharmGKB and gnomAD population databases, the minor allele frequency of rs6923761 differs by ancestry. In European populations, the minor allele frequency is approximately 0.25, while South Asian populations show a frequency closer to 0.20 [10]. A separate variant, rs10305420, located in the promoter region of GLP1R, has been associated with differential weight-loss response to GLP-1 agonists in a genome-wide association study published in Diabetes Care [11]. The clinical effect size of these variants individually is modest (0.5 to 1.2 kg difference in weight loss over 6 months), but combined with metabolic and body-composition differences, they may contribute to aggregate efficacy variation.

DPP-4 Activity and Drug Metabolism

Liraglutide is resistant to degradation by dipeptidyl peptidase-4 (DPP-4), but endogenous DPP-4 activity varies across populations. A study in the Journal of Clinical Endocrinology & Metabolism found that South Asian individuals had higher circulating DPP-4 levels compared to European controls, even after adjusting for BMI and insulin resistance [12]. While this does not directly alter liraglutide pharmacokinetics (the drug's 97% albumin binding and 13-hour half-life are well characterized), elevated DPP-4 activity may affect the incretin milieu in which liraglutide operates.

What Clinicians Should Monitor

Dr. Shivani Misra, consultant in metabolic medicine at Imperial College London, has noted: "We cannot assume that trial data generated predominantly in white European populations will translate directly to South Asian patients, who develop metabolic complications at fundamentally different body composition thresholds" [13]. Pharmacogenomic testing for GLP1R variants is not yet standard practice, but clinicians treating South Asian patients should track glycemic and weight-loss response closely during the 16-week titration period and reassess at week 16 if weight loss is <4%.

Lower BMI Thresholds and Prescribing Implications

The standard FDA-approved indication for Saxenda requires a BMI of 30 or higher (or 27 with at least one weight-related comorbidity). For South Asian patients, this threshold may be too high.

WHO and NICE Guidelines on Ethnicity-Adjusted BMI

The WHO Expert Consultation recommended that public health action for Asian populations should begin at a BMI of 23 (overweight) and 27.5 (obese), rather than 25 and 30 [1]. NICE guideline CG189 explicitly states that health professionals should "use lower BMI thresholds (23 kg/m² and 27.5 kg/m²) as triggers for action for people from Black African, African-Caribbean, and Asian (South Asian and Chinese) family backgrounds" [14].

Practical Prescribing Gaps

Despite these guidelines, prescribing algorithms for anti-obesity medications have not been systematically adjusted. A South Asian patient with a BMI of 28, two or more metabolic comorbidities, and a family history of premature cardiovascular disease may benefit from pharmacotherapy but technically falls outside the standard indication if the 30-threshold is applied rigidly. The 2022 American Association of Clinical Endocrinology (AACE) obesity algorithm acknowledges ethnicity as a factor in assessment but does not specify adjusted BMI cutoffs for pharmacotherapy initiation [15].

Cardiovascular Risk Context in South Asian Patients on Saxenda

The LEADER trial (N=9,340) demonstrated that liraglutide 1.8 mg (the diabetes dose, not the obesity dose) reduced the composite cardiovascular endpoint by 13% compared to placebo in patients with type 2 diabetes and high cardiovascular risk (HR 0.87, 95% CI 0.78 to 0.97) [16].

South Asian Cardiovascular Burden

South Asians experience coronary artery disease at rates 50% to 300% higher than European populations, and events occur roughly 10 years earlier [17]. The INTERHEART study (N=15,152 cases across 52 countries) found that South Asians had the highest population-attributable risk for myocardial infarction linked to the ApoB/ApoA1 ratio and abdominal obesity [18].

Extrapolating LEADER to the South Asian Context

LEADER did include participants from India and other South Asian countries, but ethnicity-specific cardiovascular outcome data were not reported in the primary publication. Whether the 13% risk reduction holds, exceeds, or falls short in South Asian subgroups is a clinical evidence gap. Given the amplified baseline cardiovascular risk in this population, even a modestly lower relative risk reduction could translate to substantial absolute benefit, but this remains speculative without stratified data.

Dr. Kamlesh Khunti, Professor of Primary Care Diabetes and Vascular Medicine at the University of Leicester, has stated: "South Asian populations are systematically under-represented in the landmark cardiovascular outcome trials for GLP-1 receptor agonists, which limits our ability to make evidence-based treatment decisions for the highest-risk group" [19].

Dosing Considerations for Liraglutide 3 mg in South Asian Patients

The standard Saxenda titration schedule begins at 0.6 mg daily for one week and increases by 0.6 mg weekly until reaching the target dose of 3.0 mg daily. This protocol was established in a predominantly white European trial population.

Body Weight and Dose-Response

Liraglutide pharmacokinetics are not significantly affected by body weight within the studied range (60 to 160 kg). However, South Asian patients eligible for weight-management therapy may present at lower absolute body weights than the typical SCALE participant (mean baseline weight approximately 106 kg). The clinical significance of administering 3.0 mg of liraglutide to a patient weighing 75 kg versus 106 kg has not been formally studied, but the weight-adjusted drug exposure would be roughly 40% higher in the lighter patient.

Gastrointestinal Tolerability

GI side effects (nausea, vomiting, diarrhea) were the most common adverse events in SCALE, occurring in approximately 40% of liraglutide-treated participants [5]. Smaller body size may increase the incidence or severity of GI symptoms during titration. Clinicians may consider extending the titration schedule (increasing by 0.6 mg every two weeks rather than every week) in South Asian patients who weigh <80 kg and experience significant nausea, though this approach is based on clinical judgment rather than trial data.

The 16-Week Assessment Point

Saxenda prescribing information requires reassessment at 16 weeks. If a patient has not lost at least 4% of baseline body weight, discontinuation should be considered. For South Asian patients starting at a lower BMI, a 4% loss may represent a smaller absolute weight reduction (e.g., 3.2 kg for an 80-kg patient vs. 4.2 kg for a 106-kg patient). Clinicians should weigh the metabolic impact of even modest weight loss in this population against rigid percentage cutoffs.

Gaps in Evidence and Ongoing Research

The absence of ethnicity-stratified efficacy data for liraglutide 3 mg in South Asian patients is part of a broader representation deficit in obesity pharmacotherapy research. Several developments may begin to address this gap.

The STEP Trials and Ethnic Diversity

The STEP program for semaglutide 2.4 mg (Wegovy) has included dedicated trials in Asian populations. STEP 6 was conducted entirely in Japanese patients, and STEP 2 included a more diverse cohort than SCALE. However, "Asian" remains a broad category in most trial designs, and South Asian-specific subgroup analysis is still uncommon.

Population-Level Pharmacogenomic Studies

The South Asian Genomes & Phenomes (SAGP) initiative and UK Biobank's South Asian cohort are generating genotype-phenotype data that may eventually support pharmacogenomic-guided prescribing for GLP-1 receptor agonists. These datasets are not yet large enough to power drug-specific efficacy analyses, but early signals from GLP1R variant studies may inform future trial designs [10].

What Prescribers Should Do Now

Until South Asian-specific data are available, clinicians should apply ethnicity-adjusted BMI thresholds when evaluating Saxenda candidacy, monitor weight-loss and glycemic response closely during the first 16 weeks, consider slower titration in patients with lower body weight, and account for the amplified cardiovascular risk profile when making benefit-risk assessments. A 5% weight loss in a South Asian patient with a BMI of 28 and metabolic syndrome may carry as much or more clinical benefit as a 10% loss in a European patient with a BMI of 35 and no comorbidities.